)
Shares of Biocon were trading higher by 3% at Rs 481 on the National Stock Exchange (NSE) in early morning trade after the biopharmaceuticals major said it has received approval for its Insulin Glargine by Cofepris, the Mexican health authority, through its partner PiSA Farmaceutica.
Insulin Glargine will augment the affordable insulins therapy for diabetes management. Galactus by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, Biocon said in a release.
The stock opened at Rs 481 and touched a high of Rs 483 on the NSE so far. A combined 331,033 shares changed hands on the counter till 0927 hours on the NSE and BSE.
Insulin Glargine will augment the affordable insulins therapy for diabetes management. Galactus by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, Biocon said in a release.
The stock opened at Rs 481 and touched a high of Rs 483 on the NSE so far. A combined 331,033 shares changed hands on the counter till 0927 hours on the NSE and BSE.
